Why Is Arcus Biosciences Stock Trading Higher On Monday?
1. Arcus reported promising casdatifan data for metastatic ccRCC. 2. Confirmed overall response rate of 31% across 121 patients. 3. Median progression-free survival reached 12.2 months. 4. Data showed high patient disease control at 81%. 5. Stock increased by 7.87%, trading at $14.40.